Pre-clinical imaging is growing exponentially in research centers of many academic facilities and pharmaceutical companies. This growth is largely driven by: a) The high-visibility impact of imaging on the practice of human medicine; and, b) The emerging success of molecular imaging to speed up the development of new therapies and adapt them through translational research into the clinic. By Bioscan
With Anthony Lombardo of Bracco Diagnostics Inc., Rick Lytle of Covidien, Kathleen Deardorff of GE Healthcare Medical Diagnostics and Melissa Buchanan of Guerbet LLC.
Mayo Clinic’s Richard Robb explains how advances in three-dimensional digital imaging help surgeons locate their targets with pinpoint accuracy.
Kathleen Deardorff of GE Healthcare explains the importance of understanding risk factors